Avvisa Approves 12 New Diabetes and Obesity Pens in 2026; See Prices
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
The National Agency of Health Surveillance authorized 14 new injectable pens aimed at the treatment of type 2 diabetes and obesity in Brazil during the year 2026. The advance of the records comes from the end of the patent of Ozempic, produced by Novo Nordisk, expired on March 20, 2026. The set of approvals includes [...]
This year, Anvisa (National Agency for Health Surveillance) expanded the options of injectable medicines used in the treatment of diabetes... The post Anvisa approves 12 pens for diabetes and obesity in 2026; see what and prices appeared first in Bem Paraná.
Twelve pens for diabetes and obesity were approved by Anvisa in 2026. Photo: Special Projects Anvisa (National Agency for Health Surveillance) this year expanded the options of injectable drugs used in the treatment of type 2 diabetes and obesity. Driven by the fall of the patent of Ozempic (New Nordisk Semaglutide) in March, the market received new generic and similar drug records of the substance, as well as new options based on liraglutide.Th…
This year, Anvisa (National Health Surveillance Agency) expanded the options for injectable medicines used in the treatment of type 2 diabetes and obesity. Driven by the fall of the patent of the Ozempic (New Nordisk's Semaglutide) in March, the market received new generic and similar records of the substance, in addition to new options based on liraglutide. Read more (09/14/2026
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
